Commercial Proof of Principle Grant Competition
IP&C’s annual Commercial Proof of Principle grant competition helps advance promising SickKids discoveries or inventions towards commercial products, with a view to attract new investment, enable partnerships and create new life science-based companies. Recipients receive project funding and support services to position them for the next step on their path towards commercialization: partnership, licensing or start-up formation.
$0
Total funds awarded through PoP to support innovation at SickKids
Year | Award | Principal Investigator | Project Title | Classification |
---|---|---|---|---|
2016 | $100,000 | Dr. Charles Deber | Development of novel antimicrobial peptides against bacterial biofilms | Therapeutic |
2017 | $100,000 | Dr. Brian Kavanagh | Negative abdominal pressure for injured lungs | Medical Device |
2017 | $100,000 | Dr. Roman Melnyk | Advancing the development of a potent RAS-targeted therapeutic | Therapeutic |
2018 | $56,000 | Dr. Adrian James | Steerable Endoscopic Ear Surgery Instrument | Medical Device |
2018 | $99,680 | Dr. Jason Maynes | Machine Learning Algorithms for Toxicity and Cardiac Health (MATCH) | Therapeutic |
2018 | $148,199 | Dr. Jean-Philippe Julien | In vivo evaluation of the multabody platform for cancer immunotherapy | Therapeutic |
2019 | $100,000 | Dr. Robert Hamilton | Autoantibodies to Actin, Keratin and Connexin as biomarkers/mechanisms for Brugada Syndrome | Diagnostic |
2019 | $99,800 | Dr. Cynthia Hawkins | Clinical development of liquid biopsy for cancer detection and monitoring | Diagnostic |
2019 | $100,000 | Dr. Lynne Howell | Bioactive surfaces to prevent microbial biofilms | Medical Device |
2021 | $100,000 | Dr. Christine Bear | Developing a small molecule CFTR potentiator as a therapy for Chronic Obstructive Pulmonary Disease (COPD) or bronchitis | Therapeutic |
2021 | $100,000 | Dr. Maryse Bouchard | Novel Dynamic Foot Abduction Bar for Clubfoot Brace Treatment | Medical Device |
2021 | $100,000 | Dr. Xi Huang | Treating glioblastoma using an ion channel-targeting designer interference peptide | Therapeutic |
2022 | $100,000 | Dr. Roman Melnyk | Advancing the development of gut-restricted bile acid derivatives to treat C. difficile disease | Therapeutic |
2022 | $100,000 | Dr. Steve Prescott | Automated pain behavior testing in mice | Medical Device |
2022 | $100,000 | Dr. Xi Huang | Identifying potassium channel modulators to target brain tumor-initiating cells | Therapeutic |
TOTAL | $1,503,679 |